advertisement
Liebmann JM 11
Showing records 1 to 11 | Display all abstracts from Liebmann JM78514 Oral Memantine for the Treatment of Glaucoma: Design and Results of 2 Randomized, Placebo-Controlled, Phase 3 Studies
Weinreb RN
Ophthalmology 2018; 125: 1874-1885
78939 Racial Differences in Rate of Change of Spectral-Domain Optical Coherence Tomography-Measured Minimum Rim Width and Retinal Nerve Fiber Layer Thickness
Bowd C
American Journal of Ophthalmology 2018; 196: 154-164
78514 Oral Memantine for the Treatment of Glaucoma: Design and Results of 2 Randomized, Placebo-Controlled, Phase 3 Studies
Liebmann JM
Ophthalmology 2018; 125: 1874-1885
78939 Racial Differences in Rate of Change of Spectral-Domain Optical Coherence Tomography-Measured Minimum Rim Width and Retinal Nerve Fiber Layer Thickness
Zangwill LM
American Journal of Ophthalmology 2018; 196: 154-164
78514 Oral Memantine for the Treatment of Glaucoma: Design and Results of 2 Randomized, Placebo-Controlled, Phase 3 Studies
Cioffi GA
Ophthalmology 2018; 125: 1874-1885
78939 Racial Differences in Rate of Change of Spectral-Domain Optical Coherence Tomography-Measured Minimum Rim Width and Retinal Nerve Fiber Layer Thickness
Weinreb RN; Girkin CA
American Journal of Ophthalmology 2018; 196: 154-164
78514 Oral Memantine for the Treatment of Glaucoma: Design and Results of 2 Randomized, Placebo-Controlled, Phase 3 Studies
Goldberg I; Brandt JD
Ophthalmology 2018; 125: 1874-1885
78939 Racial Differences in Rate of Change of Spectral-Domain Optical Coherence Tomography-Measured Minimum Rim Width and Retinal Nerve Fiber Layer Thickness
Fazio MA; Liebmann JM
American Journal of Ophthalmology 2018; 196: 154-164
78514 Oral Memantine for the Treatment of Glaucoma: Design and Results of 2 Randomized, Placebo-Controlled, Phase 3 Studies
Johnson CA
Ophthalmology 2018; 125: 1874-1885
78939 Racial Differences in Rate of Change of Spectral-Domain Optical Coherence Tomography-Measured Minimum Rim Width and Retinal Nerve Fiber Layer Thickness
Belghith A
American Journal of Ophthalmology 2018; 196: 154-164
78514 Oral Memantine for the Treatment of Glaucoma: Design and Results of 2 Randomized, Placebo-Controlled, Phase 3 Studies
Zangwill LM; Schneider S; Badger H; Bejanian M
Ophthalmology 2018; 125: 1874-1885
